Counting tumor cells in blood predicts treatment benefit in prostate cancer

	Tweet

Counting the number of tumor cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, new results show.

At the ESMO Conference Lugano (ECLU) organized by the European Society for Medical Oncology, researchers showed that changes in the number of circulating tumor cells predicted the outcome after chemotherapy in this hard to treat cancer.

“The results add to a growing body of evidence showing that counting these cells is a valuable method for predicting survival and for monitoring treatment benefit in these patients”, said Dr. David Olmos from The Royal Marsden NHS Foundation Trust in the UK.

"Our study shows that circulating tumor cell counts could provide information about how patients are responding to therapy earlier than other markers such as prostate-specific antigen (PSA) or time-to-disease progression,” he said. “We have observed that patients with declining numbers of circulating tumor cells can see a change in their initial prognosis, reflecting a potential benefit from therapy.”

Among the 119 patients in the study, researchers found that those with the lowest circulating cell counts had on average the longest survival.

“Cancer cells can be detected in the circulating blood by a range of methods”, Dr. Olmos said. “The technique we used in our study is classified as a cytometric approach. We use an antibody that is widely expressed by epithelial cancer cells, and then use a range of cell-staining techniques to ensure it is a cancer cell.”

“Because these circulating cells have broken away from either primary tumors or metastatic sites in other parts of the body, they could potentially be used to help study the specific characteristics of the cancer and perhaps personalize therapy”, Dr. Olmos said.

###

Contact: Vanessa Pavinato

41-919-731-907
European Society for Medical Oncology

RELATED STORIES:
Prostate cancer hormone therapy hard on the heart   Should older men be screened for prostate cancer?   Folate may alter risk of prostate cancer progression   Association of C-peptide concentration with prostate cancer incidence in a prospective cohort   New Finding Suggests Prostate Biopsy is Not Always Necessary   Prostate cancer diagnosis raises risk of suicide   Folic Acid Supplements Linked To Higher Risk Of Prostate Cancer   Researchers identify promising cancer drug target in prostate tumors   Predicting the Return of Prostate Cancer: New Study Betters the Odds of Success   Rotating-shift work tied to prostate cancer risk   Prostate cancer increases hip fracture risk by eight times in 50 to 65 year-olds   Study examines the use of a novel suprapubic catheter in suprapubic prostatectomy   Many men struggle to work after prostate cancer   UAB Cancer Center, Urologists Affirm Men Should Take Lead in Deciding to Test for Prostate Cancer   Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy   Combination of genetic mutation and viral infection may cause prostate cancer   PSA levels accurately predict prostate cancer risk in African-American men   Drug Shows Activity in Men with Advanced Prostate Cancer   New data show benefit of finasteride in preventing prostate cancer   Prostate cancer screening: More harm than good?   Selected Men with Low-Risk Prostate Cancer Have Good Clinical Outcomes without Immediate Treatment   New Lab Evidence Suggests Preventive Effect of Herbal Supplement in Prostate Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]